tumors of GI system

Question 1

MOA of bevacizumab

Answer 1

anti VEGF

Question 2

ADE of bevacizumab

Answer 2

BBW for bleeding, GI perforation, wound dehisences

- HTN, hypersensitivity

Question 3

MOA of capecitabine

Answer 3

oral pro-drug metabolized to 5FU

Question 4

ADE of capecitabine

Answer 4

BBW - dihydropyrimidine dehydrogenase (DPD) deficiency prevents metabolic actions.
CI - renal dysfucnction, adverse CV events
-interacts w/ oral anticogaulant, courmarin
- neurologic and hematologic toxicities

Question 5

MOA of certuximab

Answer 5

EGFR mab

Question 6

ADE of certuximab

Answer 6

BBW: cardiac arrest, respiratory arrest, sudden death

- infusion rxns, acneiform rash common and severe

Question 7

MOA of cisplatin

Answer 7

forms DNA intrastrand crosslinks and adducts

Question 8

ADE cisplatin

Answer 8

OTO and nephrotoxicity, platinum HSR

Question 9

MOA Docetaxel

Answer 9

MT stabilizer inhibiting depolymerization

Question 10

ADE of docetaxel

Answer 10

BBW: bone marrow suppression, heart disease, hepatic dz, secondary malginancies, extravasational necrosis

Question 11

MOA Erlotinib

Answer 11

EGFR -TKI

Question 12

ADE Erlotinib

Answer 12

GI tox, prolonged bleeding, elevated LFTS, ocular tox, rarely interstitial lund dz

Question 13

MOA 5FU

Answer 13

pyrimidine antimetabolite that inhibits TS and interferes w/ RNA synthesis and function. Also has some effects on DNA

Question 14

ADE 5FU

Answer 14

severe hematological tox, DPD deficiency leads to enhanced neurotoxicity. DPD is needed to degrade 5FU to an inactive compound

Question 15

MOA Gemcitabine

Answer 15

DNA pol inhibitor via incorporation of triphosphate form during DNA synthesis

Question 16

ADe of Gemcitabine

Answer 16

infection, bone marrow suppession, sensory peripheral neuropathy, arthralgia, drowsiness, fatigue, anorexia,

Question 17

MOA Imatinib

Answer 17

oral TKI as adjuvant treatment following complete resection of KIt positive GIST

Question 18

ADE Imatinib

Answer 18

GI tox common, CHF in some pts. Neurologic tox, fluid retention, edema

Question 19

MOA IFN

Answer 19

Enzyme activation following cell surface receptor binding and tyrosine kinase activation

Question 20

ADE of IFN

Answer 20

neuropsychiatric evetnts - aggression, depression, and suicide
- FLS

Question 21

MOA Mitomycin

Answer 21

mono or bifunctional alkylating agent

Question 22

ADE mitomycin

Answer 22

thrombocytopenia, leuokpenia, HUS, MAHA, renal failure

Question 23

MOA of octreotide

Answer 23

somatostatin analog; reduces duodenal bicarb, amylase, reduces gastric acidity, inhibits gall bladder contractility and bile secretion, inhibits meal-induced increases in SMA and portal venous blood flow

Question 24

ADE of octroetide

Answer 24

monitor blood glucose b/c inhibits insulin and glucagon. Dose- related diarrhea

Question 25

MOA of suntinib

Answer 25

inhibits lots of RTKs

Question 26

ADE of suntinib

Answer 26

thrombocytopenia and bleeding. QT prolongation, sometimes fatal GI complications including GI perforation

Question 27

MOA Trastuzumab

Answer 27

HER2/neu mab. Downregulates HER2/neu, CDKI p27 accumulates and arrests cell cycle. Also inhibits consititutive HER2 cleavage/shedding mediated by metalloproteases

Question 28

ADE Trastuzumab

Answer 28

LVEF dysfunction and cardiomyopathy. severe infusion-related rxns including anaphylaxis, angioedema, and pulm toxicity.